A Novel In Silico Approach to Drug Discovery via Computational Intelligence

David Hecht* and Gary B. Fogel
Southwestern College, 900 Otay Lakes Road, Chula Vista, California 91910, and Natural Selection, Inc., 9330 Scranton Road, Suite 150, San Diego, California 92121
J. Chem. Inf. Model., 2009, 49 (4), pp 1105–1121
DOI: 10.1021/ci9000647
Publication Date (Web): April 6, 2009
Copyright © 2009 American Chemical Society
* Corresponding author phone: (619)421-6700; e-mail: dhecht@swccd.edu., †

Southwestern College.

, ‡

Natural Selection, Inc.

Abstract

Abstract Image

A computational intelligence drug discovery platform is introduced as an innovative technology designed to accelerate high-throughput drug screening for generalized protein-targeted drug discovery. This technology results in collections of novel small molecule compounds that bind to protein targets as well as details on predicted binding modes and molecular interactions. The approach was tested on dihydrofolate reductase (DHFR) for novel antimalarial drug discovery; however, the methods developed can be applied broadly in early stage drug discovery and development. For this purpose, an initial fragment library was defined, and an automated fragment assembly algorithm was generated. These were combined with a computational intelligence screening tool for prescreening of compounds relative to DHFR inhibition. The entire method was assayed relative to spaces of known DHFR inhibitors and with chemical feasibility in mind, leading to experimental validation in future studies.

Tools

SciFinder Links

SciFinder subscribers:  Click to sign in | Not a SciFinder subscriber? Learn more at www.cas.org

Explore by:


History

  • Published In Issue April 27, 2009
  • Article ASAPApril 06, 2009
  • Received: February 23, 2009

Recommend & Share

Related Content

Other ACS content by these authors: